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Abstract: Shiga toxin (Stx) producing Escherichia coli (STEC) is responsible for causing
hemolytic uremic syndrome (HUS), a life-threatening thrombotic microangiopathy characterized by
thrombocytopenia, hemolytic anemia, and acute renal failure after bacterially induced hemorrhagic
diarrhea. Until now, there has been neither an effective treatment nor method of prevention for the
deleterious effects caused by Stx intoxication. Antibodies are well recognized as affinity components
of therapeutic drugs; thus, a previously obtained recombinant human FabC11:Stx2 fragment was
used to neutralize Stx2 in vitro in a Vero cell viability assay. Herein, we demonstrated that this
fragment neutralized, in a dose-dependent manner, the cytotoxic effects of Stx2 on human glomerular
endothelial cells, on human proximal tubular epithelial cells, and prevented the morphological
alterations induced by Stx2. FabC11:Stx2 protected mice from a lethal dose of Stx2 by toxin-antibody
pre-incubation. Altogether, our results show the ability of a new encouraging molecule to prevent
Stx-intoxication symptoms during STEC infection.
Keywords: Shiga toxin; recombinant antibody fragment; Fab; neutralization; protection
Key Contribution: A human Fab recombinant fragment, obtained in bacteria using a phage
display technique from a synthetic library, showed promising neutralization effects against Stx2,
both in vitro and in vivo, raising new possibilities to block the cytotoxicity of the Stx2 toxin and maybe
HUS development.
1. Introduction
Shiga toxin type 2 (Stx2) is a ribotoxin produced by several strains of Shiga toxin-producing
Escherichia coli (STEC), an etiologic agent of bloody diarrhea. Stx2 consists of seven different variants
(Stx2a–Stx2g), which have high homology (93–100%), except for Stx2f (69% identity) [1]. These toxins
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are encoded by a bacteriophage genome, which can be transferred between related bacteria, resulting
in a diverse array of bacterial strains secreting one or more toxin subtypes [2].
Stx2 is part of a related bacterial toxin protein family that are similar in structure and mechanism
of action, comprised of Stx from Shigella dysenteriae and Stx1 from STEC. Stxs belong to the AB5 toxin
protein class, consisting of an enzymatically active A subunit (~32 kDa), and a homo-pentameric B
subunit (7.7 kDa per monomer) which binds to the host receptor globotriaosylceramide (Gb3) [3].
After receptor-mediated endocytosis, the Stx enzymatically active A subunit depurinates the conserved
adenine residue of 28S eukaryotic rRNA, terminating peptide elongation and leading to cell death [4].
Stx2-producing strains are more virulent than Stx1-producing ones and are frequently associated with
hemolytic uremic syndrome (HUS), a thrombotic microangiopathy characterized by thrombocytopenia,
hemolytic anemia, and acute renal failure [5]. This syndrome can lead to death or long-term
consequences such as hypertension and renal disease, because microvascular endothelial cells in
the kidney are highly sensitive to Stx [6].
Until now, there is neither an effective treatment nor prevention method for the deleterious
effects of Stx intoxication [3]. However, several strategies have been developed, such as controlling
bacterial growth without increasing Stx secretion, interference with toxin trafficking and cellular
response to the toxin. Designing antibodies against Stx is an important challenge for HUS therapy [7].
Using antibodies directed against Stx as therapy either to prevent or treat the HUS disease process
is a promising approach [8–10]. Since human microvascular endothelial cells express 50-fold higher
Gb3 levels compared to the endothelial cells of large vessels [11], they are an excellent cell model for
in vitro therapeutic studies.
Antibodies are well recognized as affinity reagents and therapeutic drugs; thus, they can be
generated with high affinity and specificity. They are also long lived in circulation and are generally
well tolerated as drugs [12]. Phage display antibody libraries provide an attractive substitute to
circumvent animal immunization and other caveats of hybridoma technology, an effective but laborious
and expensive approach to generate monoclonal antibodies [12].
A human recombinant monoclonal Fab fragment against Stx2 (FabC11:Stx2) was previously
obtained by phage display technology [13] using a synthetic library [14]. This fragment was produced
in a bacterial system, which is more feasible and economical than conventional hybridoma technology,
and showed a detection limit of 24 nM to detect Stx2 and cross-reacted to Stx1, which was confirmed
by peptide array, showing that this molecule recognizes the B subunit of both toxins, although with
higher affinity to Stx2B. This fragment also demonstrated neutralizing ability against Stx2 in Vero cell
assay. Altogether, these features suggest that this antibody fragment might be an alternative therapy
against Stx2 intoxication symptoms. Herein, the affinity and ability of this fragment, which neutralize
the toxicity of Stx2, were further evaluated by testing two different human renal cell lines and the
fragment’s ability to protect mice from Stx2 intoxication.
2. Results
2.1. FabC11:Stx2 Has High Affinity to Stx2 and Protects Human Glomerular Endothelial Cells (HGEC) and
Human Kidney (HK-2) Cells from Stx2 Cytotoxicity
First, the kinetic affinity constant (KD) of the fragment to Stx2 was determined using Surface
Plasma Resonance (SPR), since previous work had showed only the apparent affinity [13]. Using this
accurate methodology, the KD was found to be 7.54 × 10−9 M (Table 1).
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Table 1. SPR of FabC11:Stx2 for affinity determination against both Stx toxins. The monoclonal antibody
(mAb) Stx2 [15] was used as positive control. The values represent two independent Fab batches.
Sample ka (1/Ms) kd (1/s) KD (M)
Fab:C11 vs. Stx1 (4.4 ± 0.9) × 105 (1.5 ± 0.2) × 10−2 (3.4 ± 0.2) × 10−8
Fab:C11 vs. Stx2 (4.2 ± 0.2) × 104 (2.9 ± 0.1) × 10−4 (7.0 ± 0.1) × 10−9
mAb Stx2 (1.0 ± 0.2) × 104 (2.0 ± 0.3) × 10−4 (2.0 ± 0.1) × 10−8
ka, association rate constant; kd, dissociation rate constant; KD, kinetic affinity constant.
To analyze the capacity of FabC11:Stx2 to neutralize Stx2 cytotoxicity, we developed HGEC and
HK-2 viability assays by neutral red uptake assay. Cells were pre-treated with FabC11:Stx2 (0.001 to
10 µg/mL) for 1 h at 37 ◦C and then exposed to Stx2 (0.1 ng/mL) for 72 h, or cells were co-incubated
simultaneously with FabC11:Stx2 (0.001 to 10 µg/mL) and Stx2 (0.1 ng/mL) and incubated for 72 h.
The molar ratios used in these experiments were from 0.7:1 to 7000:1 for Fab:Stx2. Under both conditions
evaluated, pre-incubation and co-incubation, FabC11:Stx2 significantly neutralized the cytotoxic effects of
Stx2 on HGEC and HK-2 cells (p < 0.05, n = 3). These effects were shown to be dose-dependent. For HGEC,
the highest protection of FabC11:Stx2 was observed at 10 µg/mL. No significant differences were found
between the two experimental conditions, since cell viability with 10 µg/mL FabC11:Stx2 was 54 ± 3.0%
and 52 ± 4.0% under pre-incubation and co-incubation conditions, respectively (Figure 1A).
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Figure 1. FabC11:Stx2 protected HGEC and HK-2 against Stx2 cytotoxicity. HGEC (A) and HK-2 (B)
were pre-treated with different concentrations of FabC11:Stx2 (1 h at 37 ◦C), and Stx2 (0.1 ng/mL) was
then added, or cells were co-treated with FabC11:Stx2 (0.001 µg/mL to 10 µg/mL) and Stx2 (0.1 ng/mL)
simultaneously. After 72 h of treatment, cells were incubated with neutral red for an additional 1 h at
37◦C in 5% CO2. Absorbance of each well was read at 540 nm. One hundred percent represents cells
incubated under identical conditions but without FabC11:Stx2 or toxin treatment (Ctrl). Results are
expressed as means ± SEM of three experiments, pre/co-incubation vs. Stx2, * p < 0.05; pre-incubation
vs. co-incubation, # p < 0.05.
In addition, the loss of HK-2 viability was significantly inhibited with lower FabC11:Stx2
concentrations (0.001 µg/mL), compared to HGEC (1 µg/mL) (Figure 1B). Furthermore, pre-incubation
with 0.001–1 µg/mL FabC11:Stx2 w s more effective than co-incubation (FabC11:Stx2 1 µg/mL) i
neutralizing Stx2 cytotoxicity (100 ± 2.0% vs. 82.0 ± 3.0%) neutralization activity of Stx2 in HK-2
was 100% with 1 µg/mL and 10 µg/mL FabC11:Stx2 for pre-incubation and co-incubation, respective y.
2.2. FabC11:Stx2 Prevents Morphological Alterations Induced by Stx2 in HGEC and HK-2 Cells
As previously described, Stx2 causes morphological alterations associated ith cell detachment
and intracellular edema on HGEC and HK-2 cells [7,16]. Therefore, the morphology of HGEC and HK-2
cells treated with Stx2 and in the presence of FabC11:Stx2 antibodies was analyzed. The results showed
that this recombinant antibody fragment significantly decreased cell detachment and intracellular
edema caused by Stx2 in HGEC (Figure 2) and HK-2 cells (Figure 3). No significant differences were
found for prevention of HGEC or HK-2 cell detachment between pre-incubation and co-incubation
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conditions (Figures 2B and 3B). However, prevention of HGEC intracellular edema was higher with
pre-incubation than co-incubation (Figure 2C), and, on the contrary, prevention of HK-2 intracellular
edema was higher with co-incubation than pre-incubation (Figure 3C).Toxins 2018, 10, x FOR PEER REVIEW  4 of 10 
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2.3. FabC11:Stx2 Protected Mice Injected with a Lethal Dose of Stx2  
Figure 2. FabC11:Stx2 protects HGEC from Stx2-induced morphological disturbances. HGEC seeded
on gelatin-coated glass coverslips was pre-treated with FabC11:Stx2 (10 µg/mL, 1 h at 37 ◦C), and Stx2
(0.1 ng/mL) was then added. Co-incubation was performed by adding FabC11:Stx2 (10 µg/mL) with
Stx2 (0.1 ng/mL) simultaneously. After 72 h of treatments, cells were stained with Hematoxylin and
Eosin (H&E) and the morphology (A) and number of HGEC (B) were analyzed by light microscopy
(×200 and×400). HGEC areas (C) were measured using ImageJ software. The black arrows indicate the
morphological changes such as intracellular edema (thick arrows) and elongated shape (thin arrows).
Results are expressed as means ± SEM of three experiments. One hundred percent represents values
of controls. Stx2 vs. Ctrl, * p < 0.05. Pre/co-incubation vs. Stx2, # p < 0.05.
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Figure 3. FabC11:Stx2 protects HK-2 from Stx2-induced morphological disturbances. HK-2 seeded on
glass coverslips was pre-t eated with FabC11:Stx2 (10 µg/ L, 1 h at 37 ◦C), and Stx2 (0.1 ng/mL) was
the added. Co-incubation was p rformed by adding FabC11:Stx2 (10 µg/mL) with Stx2 (0.1 ng/mL)
simultaneously and incubating cells for 72 h. Finally, cells were stained with H&E, and the morphology
(A) and nu ber of HK-2 (B) were analyzed by light microscopy (×200 an ×400). HK-2 areas
(C) were measured using ImageJ software. The black arrows indicate the morphological changes,
n mely intrac llular edema (thick arrows) and elongated shape (thin arrows). R sults are expressed as
means ± SEM of three experim nts. One hund ed percent repres nt values of controls. Stx2 v . Ctrl,
* p < 0.05. Pre/co-i cubation vs. Stx2, # p < 0.05.
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2.3. FabC11:Stx2 Protected Mice Injected with a Lethal Dose of Stx2
To further analyze the protective capacity of FabC11:Stx2, we challenged adult mice with a lethal
dose (1 LD100) of rStx2. The molar ratio used in this experiment was 2 × 106: 1 Fab:Stx2, which means
144 µg of Fab/mouse. Figure 4A shows that 100% of mice injected with 1 LD100 Stx2 pre-incubated
with FabC11:Stx2 survived, compared to mice injected with rStx2 pre-incubated in PBS (0% survival).
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Figure 4. In vivo neutralizing activity of FabC11:Stx2. (A) In vivo protection against a lethal challenge
with recombinant Stx2 (rStx2). Six adult BALB/c mice were challenged with an intravenous (i.v.)
injection of 1 LD100 of Stx2 pre-incubated with PBS (Stx2) or FabC11:Stx2 (FabC11:Stx2), as detailed
in Materials and Methods. The two survival curves were statistically different by the log-rank
(Mantel–Cox) test (p < 0.02). (B) Plasma urea nitrogen levels (mg %) were determined at 72 h after
Stx2 intoxication. Each bar represents the mean ± SEM of 3 mice from each group. * p < 0.02 vs. Stx2
intoxicated mice by unpaired t-test.
Plasma urea levels were measured in these mice as a functional parameter of kidney damage and
indicator of Stx2 toxicity. As seen in Figure 4B, mice injected with 1 LD100 of rStx2 in the presence of
FabC11:Stx2 showed normal urea levels. In contrast, high urea levels were observed in Stx2-injected
mice, demonstrating the efficacy of FabC11:Stx2 against Stx2 toxicity.
3. Discussion
HUS is the major and more complicated pathology related to STEC infections, leading to
death or severe sequelae, in which Stx toxins are the main STEC virulence factors. Consequently,
its neutralization is a critical therapeutic approach. Since the first STEC outbreak in 1982, several
studies have been dedicated to Stx neutralization strategies and HUS prevention. However, to date,
to treat or prevent HUS, only a few molecules have reached trials phase I and II.
Indeed, SYNSORB Pk, a receptor analogue which in theory binds to free Stx in the infected
patient’s gut, prevents the toxin from acting either locally or systemically [17]. The antibody
urtoxazumab (TMA-15), a humanized monoclonal antibody against the Stx2 B subunit was well
tolerated in phase I studies [18] and reached phase II, but data on efficacy has not yet been published.
The humanized antibodies cαStx1 and cαStx2 against both Stx1 and Stx2 B subunits were also shown
to be well tolerated in phase I studies [19] and are now in phase II trials [10]. In summary, the few
promising molecules for preventing Stx effects and HUS development are still clinically unavailable
because they are still under investigation, or because studies were inconclusive for their therapeutic
use. Thus, at present, there is no treatment to prevent the occurrence of HUS and other complications
caused by STEC.
Toxins 2018, 10, 508 6 of 10
Although monoclonal antibodies (mAb), a growing category of pharmaceutical proteins,
are generated dominantly by hybridoma technology, advances in in vitro selection technology, such as
phage display, allows mAb generation with less time and cost compared to hybridoma procedures [20].
With this technique, human antibodies can be obtained directly without needing the cumbersome
humanization of murine antibodies. Furthermore, some synthetic libraries consist of a highly stable
framework, which minimizes immunogenicity, ideal for a therapeutic molecule [21]. Moreover,
some bacterial systems for recombinant expression and purification, such as FabC11:Stx2 [13],
are lower-cost alternatives for production of these antibodies [22].
It has been shown that Stx2 is more lethal than Stx1 in animal models, and it is also the main cause
of severe outcomes of STEC infections in humans and HUS development [3]. The FabC11:Stx2 antibody
binds to the Stx2 B subunit with high affinity (7.54 × 10−9 M) and cross-reacts with Stx1; additionally,
it is capable of neutralizing Stx2 in vitro. In addition, here we demonstrated that FabC11:Stx2 protected
against loss of cell viability and altered morphology of HGEC primary culture and the HK-2 cell
line due to Stx2 cytotoxicity. We found that HK-2 cells were protected by lower concentrations of
FabC11:Stx2 than HGEC, and pre-incubation treatment was more effective than co-incubation. On the
contrary, HGEC cell protection was only obtained at the highest concentrations of FabC11:Stx2; assayed
and pre-incubation and co-incubation conditions gave the same protection.
In diarrhea-associated HUS, kidneys are the organs predominantly damaged by Stx, because
of the existence of microvascular endothelial cells, which express high levels of Gb3 [11]. We have
previously shown that HGEC and HK-2 cells exhibited the same sensibility to Stx2 [7]. Taking this
into account, the differences between the protection of HGEC and HK-2 could be due to a possible
competition effect between Gb3 receptor and FabC11:Stx2 antibody for binding Stx2, or because of a
different availability of FabC11:Stx2 antibodies in the cellular environment. In this sense, endocytosis
of Fab fragments by endothelial cells have been previously described [23], so the concentration of
antibodies to neutralize the toxin could decrease.
In an in vivo mouse model, FabC11:Stx2 protected mice from death after a lethal dose of Stx2.
The non-protected intoxicated animals exhibited high urea concentrations after 72 h, suggesting that
they died from kidney damage related to Stx2 cytotoxicity. Tests with separate inoculation of Stx2 and
the antibody did not show protection (data not shown). The inability of Fab fragments to protect in an
in vivo model without prior incubation with the target toxin was also shown by Akiyoshi et al. [24],
with Fab and F(ab)2 against Stx2 B subunit, and by Mejías et al. [9] with VHH produced in camelids
also against Stx2. This may be explained by the molecular weight cutoff of around 30–50 kDa for
glomerular filtration [25]. Since the predicted size of FabC11:Stx2 is 48 kDa, this may be too close to the
cutoff, resulting in a decreased half-life for this fragment in the circulation, where the antibody would
be cleared from the animal’s blood before encountering the toxin. This could be improved by fusion to
a long-lived serum protein such albumin as demonstrated by Mejías et al. [9], or by transforming the
Fab fragment into a full-length IgG4 antibody by sub-cloning, which is currently being done by our
group. The plasticity of the recombinant molecule makes it possible in an easier manner compared
with monoclonal antibodies from hybridoma.
In summary, the results obtained with FabC11:Stx2 showed that this Fab recombinant fragment
was able to prevent Stx2 toxicity to human kidney cells and in mice. Thus, we conclude that FabC11:Stx2
is an encouraging therapeutic tool for neutralizing the effects of Stx2 and preventing HUS development,
even though more investigations are needed regarding the efficacy of this protection in vivo.
4. Materials and Methods
4.1. Reagents
Purified Stx2a is commercially available and obtained from Phoenix Laboratory, Tufts Medical
Center, Boston, MA, USA. Recombinant Stx2 (rStx2) was expressed and purified as previously
described [26]. FabC11:Stx2 recombinant antibodies were produced as previously reported [14].
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4.2. FabC11:Stx2 Affinity by Surface Plasmon Ressonance
The surface plasmon resonance was performed and analyzed using a BIAcore T200 instrument
(GE Healthcare, Uppsala, Sweden), following the manufacturer’s recommendations. In summary,
a censor chip (CM5) was prepared for immobilization of Stx2 or Stx1 (5 µg/mL) in 10 mM sodium
acetate buffer, pH 5.5 (152 RU) and activated by N-ethyl-N-(dimethylaminopropyl) carbodiimide
(EDC) and N-hydroxysuccinimide (NHS) in a mix of equal amounts. The HEPES-EDTA (HBS-EP
buffer, pH 7.4, containing 10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05% Tween 20 was used
as running buffer and the samples were prepared in HBS-EP buffer (0–7.4 µM, twofold dilutions).
A multicycle model held at 25 ◦C and a 30 µL/mL flow rate (120 s contact and 600 s dissociation)
was performed for kinetic study. The sensor chip regeneration was performed between cycles using
a 15 µL pulse of 100 mM glycine plus 2 M MgCl2, with a pH of 2. The experiments were performed
in duplicate and using the Langmuir 1:1 binding model, the KD was calculated by BIAevaluation 3.0
(GE Healthcare, Uppsala, Sweden).
4.3. Primary Culture
Human glomerular endothelial cells (HGEC) were obtained from kidney fragments of different
human pediatric patients, which were undergoing nephrectomy at Hospital Nacional “Alejandro
Posadas,” Buenos Aires, Argentina. Patients exhibited either segmental uropathies or a tumor
in one pole and normal values of creatinine. Fragments were taken from kidney normal areas.
Written informed consent was obtained from the next of kin, caretakers, or guardians on behalf of
the minors/children participating in our study. The study was conducted in accordance with the
Declaration of Helsinki, and the protocol was approved by the Ethics Committee “Dr. Vicente Federico
Del Giúdice” of the Hospital Nacional “Alejandro Posadas” (035LUP1So/17(13)). Experiments were
developed in growth-arrested conditions by using a medium M199 with 10% fetal bovine serum (FBS),
3.2 mM L-glutamine and 100 U/mL penicillin/streptomycin (P/E), and without an endothelial cell
growth supplement. Cells were used between 2–7 passages, after endothelial characterization, as was
previously described [16].
4.4. Cell Line Culture
Human proximal tubular epithelial cell line (HK-2) was grown in Dulbecco’s Modified Eagle
Medium (DMEM F12) (Sigma Aldrich, St. Louis, MO, USA) with 10% FBS, 1% P/E (GIBCO, Invitrogen,
Carlsbad, CA, USA), 2 mM L-glutamine, 15 mM HEPES at 37 ◦C in a humidified 5% CO2 incubator.
Experiments were developed in growth-arrested conditions with DMEM/F12 medium without FBS.
4.5. Stx2 Neutralization Assay in HGEC and HK-2
For neutralization assays, HGEC and HK-2 cells were treated using two different protocols.
For pre-incubation assays, cells were pre-treated with different concentrations of FabC11:Stx2 (1 h at
37 ◦C) and then exposed to Stx2 for 72 h. For co-incubation assays, cells were treated simultaneously
with FabC11:Stx2 and Stx2 for 72 h. FabC11:Stx2 concentrations used ranged from 0.001 to 10 µg/mL.
Stx2 was assayed at the dilution required to kill 50% of cells (1 CD50 = 0.1 ng/mL). The molar ratios
used ranged from 0.7:1 to 7000:1 for Fab:Stx2. Finally, cell viability was analyzed as is described below.
4.6. Neutral Red Cytotoxicity Assay
HGEC and HK-2 cell viability was analyzed by neutral red uptake assay, as was previously
described [27]. HGEC and HK-2 cells were grown to confluence in 96-well plates with a complete
medium. Treatments were developed for 72 h and then freshly diluted neutral red (Sigma Aldrich,
St. Louis, MO, USA) was incorporated to a final concentration of 10 mg/mL. After that, cells were
incubated for an additional 1 h at 37 ◦C in 5% CO2. Finally, cells were washed and fixed with
1% CaCl2/1% formaldehyde and then lysed with 1% acetic acid in 50% ethanol. Absorbance was
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measured in an automated plate spectrophotometer at 540 nm. Results were expressed as percentage of
viability, where 100% represents cells incubated under identical conditions but without toxin treatment.
Percentage of cell death prevention was calculated considering 100% protection when Stx2 cytotoxic
effects were totally reversed.
4.7. Cell Morphology Analysis
HGEC and HK-2 cells were seeded on glass coverslips (12 mm), washed with PBS at pH 7.4 and
treated as described above. For these experiments, 10 µg/mL FabC11:Stx2 was used. After incubation,
cells were fixed for 2 h at room temperature with 96% v/v alcohol, stained with hematoxylin/eosin
(H&E), and examined by light microscopy (×200 and ×400, Zeiss Axiophot, Zeiss, Heidelberg,
Germany). To obtain the percentage of cells/field, photographs of 10 randomly selected fields were
taken and then cells were counted and averaged. The percentage of cells per field was calculated
considering the average number of control cells as 100% (percentage of cells/field = (number of treated
cells × 100)/number of control cells). From the same photographs, the percentage of cell area was
calculated; the cell area in each cell was analyzed using the ImageJ software (NIH) according to the
manual instructions. The average of the cell areas was calculated in each condition and the control
cell area was considered as 100% (percentage of cell area/field = (cell area of treated cells × 100)/cell
area of control cells). Results are expressed as means ± SEM. Percentages of cell detachment and
intracellular edema prevention were calculated considering 100% protection when these effects were
totally reversed.
4.8. In Vivo Stx2-Neutralizing Capacity
BALB/c mice were bred in the animal facilities of the Instituto de Medicina Experimental (IMEX),
Buenos Aires. The experiments performed in the present work were approved by the IMEX Care
Committee (ethical approval code: CICUAL No. 34/17, date of approval: 24 May 2017) in accordance
with the principles set forth in the Guide for the Care and Use of Laboratory Animals. Throughout
the studies, the health and behavior of the mice were assessed three times a day. Any unnecessary
pain, discomfort, or injury to animals was avoided. To test in vivo Stx2-neutralization activity and
protective capacity of FabC11-anti-Stx2 antibody (FabC11:Stx2), rStx2 (one lethal dose of 100%, 1 LD100,
1 pmol/mouse) was pre-incubated with FabC11:Stx2 (2 µmol/mouse) or with PBS as negative control,
for 1 h at 37 ◦C and 1 h at 4 ◦C. The mixture was injected intravenously into naive adult Balb/c mice
and survival was checked. For each group of experiments, three mice were tested. Blood samples were
obtained at 72 h for determination of blood urea nitrogen in plasma. Biochemical determinations of
urea in mouse plasma were performed with a commercial kit (Wiener Lab, Buenos Aires, Argentina).
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